lrrc40 Antibody

What is LRRC40 and what applications are LRRC40 antibodies validated for?

LRRC40 (Leucine-rich repeat-containing protein 40) is a protein-coding gene that produces a leucine-rich repeat-containing protein. According to current research, commercial LRRC40 antibodies have been validated for multiple applications including:

When designing experiments, researchers should prioritize antibodies that have been specifically validated for their application of interest, as performance can vary significantly across different experimental contexts .

What species reactivity is available for LRRC40 antibodies?

LRRC40 antibodies are available with reactivity against several species, though human-reactive antibodies are most common:

When working with non-human samples, researchers should verify sequence homology between species and consider using antibodies raised against immunogens with high sequence conservation . For mouse studies specifically, some antibodies have been validated with 80-81% antigen sequence identity to the human ortholog .

How should researchers select the appropriate LRRC40 antibody for their experiments?

Selection of an appropriate LRRC40 antibody requires consideration of multiple factors:

• Target epitope region: Different antibodies recognize distinct regions of LRRC40

  • C-terminal antibodies (e.g., amino acids 343-371)

  • Full-length protein antibodies (1-602AA)

  • LRR domain-specific antibodies

• Clonality considerations:

  • Polyclonal antibodies: Available from rabbit hosts, offering broad epitope recognition

  • Monoclonal antibodies: Available as mouse monoclonal (e.g., clone 3E10) for specific epitope targeting

• Validation data: Prioritize antibodies with multiple validation methods

  • Western blot showing expected molecular weight (~68-80 kDa)

  • Knockout/knockdown validation

  • Peptide competition assays

• Format needs:

  • Unconjugated for most applications

  • FITC-conjugated for direct fluorescence detection

  • Other conjugates (e.g., HRP, biotin) available for specialized applications

Researchers should request complete validation data from manufacturers, including images showing antibody performance in their specific application and cell/tissue type .

What methods are recommended for validating LRRC40 antibody specificity?

Proper validation of LRRC40 antibodies is critical for ensuring experimental reliability:

• Knockout/knockdown validation:

  • Use CRISPR/Cas9 LRRC40 knockout cell lines (e.g., HEK293 LRRC40 KO)

  • Compare with parental wild-type cells to confirm signal loss

  • Alternative: siRNA knockdown using pooled siRNAs targeting LRRC40

• Peptide competition assays:

  • Pre-incubate antibody with purified recombinant LRRC40 protein

  • Signal should be eliminated or significantly reduced in competed samples

• Molecular weight verification:

  • LRRC40 appears at approximately 68 kDa (calculated MW: 68.1 kDa)

  • Some detection methods may show slight variations (68-80 kDa)

• Recombinant protein as positive control:

  • Use purified recombinant LRRC40 protein as a standard

  • Compare migration pattern with endogenous protein

• Tissue expression pattern analysis:

  • Highest expression reported in brain, lung, kidney and spleen

  • Verify detection matches known expression patterns

For rigorous validation, multiple methods should be employed, and researchers should consider independent verification with at least two different antibodies targeting distinct epitopes .

What are optimal protocols for using LRRC40 antibodies in Western blotting?

For successful Western blot detection of LRRC40, researchers should follow these optimized protocols:

• Sample preparation:

  • Use RIPA or NP-40 based lysis buffers with protease inhibitors

  • For tissue samples, highest LRRC40 expression is detected in brain, lung, and kidney

• Gel electrophoresis conditions:

  • Use 8-10% SDS-PAGE gels for optimal resolution

  • Load sufficient protein (30-50 μg of total protein per lane)

• Transfer and blocking:

  • PVDF membrane is recommended for LRRC40 detection

  • Block with 5% non-fat dry milk or BSA in TBST

• Antibody incubation:

  • Primary antibody dilutions:

    • 0.04-0.4 μg/mL for affinity-purified antibodies

    • 1:1000 for most commercial antibodies

  • Incubate overnight at 4°C for best results

• Detection system:

  • HRP-conjugated secondary antibodies at 1:5000-1:10000

  • ECL detection with exposure times of 30 seconds to 5 minutes

• Expected results:

  • LRRC40 should appear at approximately 68 kDa

  • Multiple bands may indicate isoforms or degradation products

To verify specificity, use LRRC40 knockout samples or competing peptide as negative controls . For optimal band clarity, researchers should test multiple antibody concentrations and find the balance between specific signal and background .

How should LRRC40 antibodies be optimized for immunohistochemistry applications?

For immunohistochemical detection of LRRC40 in tissues, researchers should consider these methodology aspects:

• Tissue preparation:

  • Formalin fixation and paraffin embedding (FFPE) is compatible with most LRRC40 antibodies

  • Optimal section thickness: 4-5 μm

• Antigen retrieval:

  • Heat-induced epitope retrieval using citrate buffer (pH 6.0)

  • Pressure cooker method (20 minutes) often yields better results than microwave

• Antibody optimization:

  • Recommended dilution range: 1:50-1:200

  • Titrate antibody to determine optimal concentration

  • Incubation: overnight at 4°C for best signal-to-noise ratio

• Detection system:

  • HRP-polymer detection systems minimize background

  • DAB substrate for permanent slides or fluorescent secondary antibodies

• Counterstaining and mounting:

  • Hematoxylin counterstain for brightfield

  • DAPI nuclear counterstain for fluorescence

  • Use aqueous mounting medium for fluorescent detection

• Controls:

  • Positive control: tissues with known LRRC40 expression (brain, kidney, lung)

  • Negative control: omission of primary antibody

  • Ideally, LRRC40 knockout tissues or peptide-absorbed antibody

For multi-color staining, researchers should verify antibody compatibility with other detection reagents and consider sequential staining protocols to minimize cross-reactivity .

How can LRRC40 knockout models be generated and validated using antibodies?

LRRC40 knockout models serve as valuable tools for functional studies and antibody validation:

• CRISPR/Cas9 knockout generation:

  • Design sgRNAs targeting early exons of LRRC40

  • For LRRC40 gene editing, pairing sgRNAs to create large deletions facilitates knockout validation by PCR

  • Transfect cells with CRISPR components using reliable transfection reagents like Mirus TransIT-LT1

  • Select transfected cells using puromycin (3 μg/mL for 72 hours)

• Screening knockout clones:

  • Isolate monoclonal cell lines by single-cell dilution

  • PCR screening using primers flanking the targeted region

  • Confirm deletions by gel electrophoresis and Sanger sequencing

  • Quantify modification rates using TIDE algorithm

• Antibody-based validation:

  • Western blot: Complete absence of LRRC40 band in knockout cells

  • Immunofluorescence: Loss of specific staining pattern

  • Flow cytometry: Shift in population compared to wild-type cells

• Rescue experiments:

  • Re-express LRRC40 in knockout cells using lentiviral vectors

  • Confirm restoration of expression by antibody-based methods

  • Functional rescue validates both knockout and antibody specificity

• Available models:

  • HEK293 LRRC40 knockout cells are commercially available

  • Mouse models can be created using similar strategies

For proper validation, researchers should use multiple antibodies targeting different epitopes and combine antibody-based detection with genomic and transcriptomic confirmation methods .

What is known about LRRC40 function and how can antibodies contribute to functional studies?

While LRRC40 remains relatively understudied, antibodies are critical tools for elucidating its function:

• Current knowledge about LRRC40:

  • Contains leucine-rich repeat domains, typically involved in protein-protein interactions

  • Expressed in multiple tissues with highest levels in brain, lung, kidney, and spleen

  • May play roles in intracellular signaling and gene regulation

  • Expression increases during postnatal development, suggesting importance in mature tissue function

• Functional studies using antibodies:

  • Protein interaction studies:

    • Immunoprecipitation with LRRC40 antibodies can identify binding partners

    • Co-immunoprecipitation followed by mass spectrometry enables unbiased interactome analysis

  • Localization studies:

    • Immunofluorescence microscopy using LRRC40 antibodies determines subcellular localization

    • Co-localization with organelle markers helps establish functional compartments

  • Expression regulation:

    • Western blot analysis under various conditions can reveal expression patterns

    • Chromatin immunoprecipitation (ChIP) can identify transcription factors regulating LRRC40

• Clinical relevance investigation:

  • Tissue microarray analysis with LRRC40 antibodies can assess expression in disease states

  • Correlation with clinical outcomes may identify biomarker potential

• Signaling pathway analysis:

  • Phospho-specific antibodies (if available) can track LRRC40 activation

  • Antibody-based quantification following pathway stimulation or inhibition

Researchers should utilize multiple experimental approaches alongside antibody-based methods to comprehensively characterize LRRC40 function .

What are common issues when using LRRC40 antibodies and how can they be resolved?

Researchers frequently encounter these challenges when working with LRRC40 antibodies:

• Weak or absent signal issues:

  • Problem: No detection of LRRC40 in samples

  • Solutions:

    • Increase protein loading (50-80 μg total protein)

    • Use tissues with high expression (brain, lung, kidney)

    • Optimize antibody concentration and incubation time

    • Try enhanced detection systems (amplification reagents)

    • Verify sample preparation preserves protein integrity

• Multiple bands in Western blot:

  • Problem: Extra bands besides the expected 68 kDa LRRC40 band

  • Solutions:

    • Use freshly prepared samples with protease inhibitors

    • Verify antibody specificity with knockout controls

    • Test different blocking reagents (milk vs. BSA)

    • Reduce antibody concentration to minimize non-specific binding

    • Consider that additional bands may represent isoforms or post-translational modifications

• High background in immunohistochemistry:

  • Problem: Non-specific staining obscuring specific LRRC40 signal

  • Solutions:

    • Optimize blocking (longer time, different blocking agents)

    • More stringent washing (increase detergent concentration or washing duration)

    • Reduce primary and secondary antibody concentrations

    • Use IgG-free BSA for diluting antibodies

    • Consider biotin/avidin blocking if using biotin-based detection

• Inconsistent results across experiments:

  • Problem: Variable detection of LRRC40 between replicates

  • Solutions:

    • Standardize sample preparation and storage protocols

    • Aliquot antibodies to avoid freeze-thaw cycles

    • Include consistent positive controls in each experiment

    • Maintain detailed laboratory records of conditions

For optimal results, researchers should validate each new antibody lot and establish standardized protocols specific to their experimental system .

How can researchers select appropriate controls for LRRC40 antibody experiments?

Proper controls are essential for accurate interpretation of LRRC40 antibody experiments:

• Positive controls:

  • Recombinant LRRC40 protein:

    • Purified protein serves as size standard and positive control

    • Available as recombinant human LRRC40 with various tags

  • High-expressing tissues/cells:

    • Brain, lung, and kidney tissue lysates show strong expression

    • HEK293 cells express detectable levels of endogenous LRRC40

• Negative controls:

  • Genetic knockout/knockdown:

    • LRRC40 knockout cell lines provide definitive negative controls

    • siRNA-mediated knockdown samples show reduced signal

  • Antibody controls:

    • Pre-immune serum or isotype control antibodies

    • Primary antibody omission control

    • Peptide competition/absorption to neutralize specific binding

• Procedural controls:

  • Loading controls for Western blot (β-actin, GAPDH, etc.)

  • Tissue controls for IHC (known positive and negative tissues)

  • Staining controls for IF (secondary-only, nuclear counterstain)

• Validation controls:

  • Multiple antibodies targeting different LRRC40 epitopes

  • Alternative detection methods (e.g., mass spectrometry)

  • Genetic rescue experiments restoring LRRC40 expression

A comprehensive control strategy should include at minimum one positive control, one negative control, and appropriate procedural controls for each experiment .